TNSN08222A1 - New compounds - Google Patents

Abstract

The present invention relates to new mGluRI and mGluR5 receptor subtype preferring ligands of formula (1) wherein If) X represents a group selected from SO, S02; Y represents a group selected from (CHvn' NH, NHCHz; n is an integer of 0 to I; Z ~ is H or monosubstituted by alkyl, nitro, halogen, alkoxy, trif1uOfomelhyl, cyano, amino, alkylamino, dialkyl"mino, aminomethyl, N alkylaminomethyl, dialkylaminomelhyJ, hydroxyl. alkylsulfonylamino; R1 is an optionally substituted aJkyl, cycloalkyl, phenyl, t'- biphenyl. heterocyclyl; Rz is an optionally substituted phenyl, heterocyclyl, or NR3R, group wherein R3 and R, arc independently o selected from the group of hydrogcn and an optionally substituted alkyl, or R3 and R, togclhcr with the N atom to which they arc t=::: ilttached form an optionally substituted CS.7 heterocyclyl group, containing one or more heleroatom(s), or NlI-CO-NRsR6 group, o wherein Rs and R<; arc independently selected from the group of hydrogen and an optionally substituted alkyl, or Rs and RG to¬O gether with the N atom to which they are attached form an optionally substituted CS•7 heterocyelyl group, containing one or 1110re N heteroatom(s); and/or hydrates and/or solvates and/or pharmaceutically acceptable salts thereof formed with acids or bases. to the o processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevcntion :>- of pathological conditions which requirc the modulation of mGluRI and mGluR5 reecptors such as neurological disorders, psychi¬~ alric disorders, acule and chronic pain, neuromuscular dysfunctions of the lower urinary tract ilnd gastrointcstinal disorders.